MTA2 and Alzheimer disease: The study used human post mortem cerebral sections from the Netherlands Brain Bank (NBB), sampled from individuals for whom definitive clinicopathological diagnoses were AD (n = 15), CBD (n = 5), PiD (n = 5), FTLD (n = 10) and non-demented control participants (CTL, n = 5).